Edesa Biotech, Inc. (EDSA) Financial Ratios
17 years of historical data (2009–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.58
↓-30% vs avg
5yr avg: 3.67
30Y Low1.1·High122.3
ROE
↑
-99.6%
↓+21% vs avg
5yr avg: -126.0%
30Y Low-370%·High-30%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EDSA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Edesa Biotech, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $50M | $14M | $14M | $13M | $14M | $89M | $69M | $29M | $28M | $8M | $148M |
| Enterprise Value | $39M | $3M | $13M | $7M | $6M | $81M | $62M | $24M | $24M | $3M | $141M |
| P/E Ratio → | -4.45 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 211.25 | 69.56 | 131.79 | 34.65 | 116.60 |
| P/B Ratio | 2.58 | 1.13 | 7.18 | 1.79 | 1.44 | 6.83 | 10.47 | 5.44 | 2.47 | 1.07 | 12.04 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EDSA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | 189.81 | 57.31 | 111.84 | 14.63 | 110.77 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
EDSA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -99.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 94.6% | 75.3% | -110.2% | -134.1% | 11.3% |
| Operating Margin | — | — | — | — | — | — | -1946.7% | -689.3% | -2397.1% | -2288.6% | -386.0% |
| Net Profit Margin | — | — | — | — | — | — | -1935.6% | -662.3% | -2378.6% | -2203.7% | -395.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -99.6% | -99.6% | -136.7% | -101.9% | -156.3% | -135.5% | -107.1% | -32.9% | -53.9% | -51.0% | -49.5% |
| ROA | -82.9% | -82.9% | -97.1% | -81.8% | -134.2% | -105.3% | -77.2% | -31.1% | -51.7% | -48.7% | -43.1% |
| ROIC | -452.3% | -452.3% | -383.2% | -337.3% | -360.8% | -724.9% | — | -58.3% | -77.0% | -101.4% | -82.3% |
| ROCE | -109.6% | -109.6% | -155.0% | -111.8% | -162.9% | -211.8% | -88.4% | -34.2% | -54.4% | -53.0% | -48.3% |
EDSA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $11M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.01 | 0.01 | 0.00 | 0.01 | 0.02 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.87 | -0.51 | -0.75 | -0.75 | -0.59 | -1.06 | -0.96 | -0.37 | -0.62 | -0.60 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($11M) exceeds total debt ($0)
EDSA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Edesa Biotech, Inc.'s current ratio of 10.67x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.53x to 10.67x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.67 | 10.67 | 0.91 | 3.53 | 4.25 | 8.29 | 5.30 | 12.23 | 21.60 | 21.06 | 19.40 |
| Quick Ratio | 10.67 | 10.67 | 0.91 | 3.53 | 4.25 | 8.29 | 5.30 | 12.70 | 21.14 | 20.85 | 19.00 |
| Cash Ratio | 10.01 | 10.01 | 0.57 | 2.94 | 3.31 | 5.37 | 4.72 | 10.90 | 20.88 | 20.46 | 18.29 |
| Asset Turnover | — | — | — | — | — | — | 0.03 | 0.07 | 0.02 | 0.03 | 0.10 |
| Inventory Turnover | — | — | — | — | — | — | — | — | 1.99 | 7.85 | 4.52 |
| Days Sales Outstanding | — | — | — | — | — | — | 97.07 | 192.86 | 71.06 | 2.06 | 24.63 |
EDSA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Edesa Biotech, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $3M | $3M | $2M | $2M | $1M | $655318 | $478229 | $23810 | $210150 |
Peer Comparison
Compare EDSA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EDSAYou | $50M | -4.4 | — | — | — | — | -99.6% | -452.3% | — |
 ADMA | $2B | 13.9 | 9.6 | 69.3 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 NUVB | $2B | -7.9 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 HALO | $8B | 27.6 | 11.5 | 13.0 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 ARQT | $3B | -189.2 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 SLDB | $563M | -3.6 | — | — | — | — | -109.9% | -120.8% | — |
 VYNE | $28M | -1.1 | — | — | 96.0% | -5219.1% | -66.3% | -124.0% | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 CRL | $9B | -64.6 | 13.1 | 17.5 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 17 years · Updated daily
What if you invested $1,000 in EDSA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in EDSA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs EDSA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationEDSA vs ADMA — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs ADMA Biologics, Inc..
Compare NowEDSA — Frequently Asked Questions
Quick answers to the most common questions about buying EDSA stock.
What is Edesa Biotech, Inc.'s P/E ratio?
Edesa Biotech, Inc.'s current P/E ratio is -4.4x. This places it at the 50th percentile of its historical range.
What is Edesa Biotech, Inc.'s ROE?
Edesa Biotech, Inc.'s return on equity (ROE) is -99.6%. The historical average is -112.3%.
Is EDSA stock overvalued?
Based on historical data, Edesa Biotech, Inc. is trading at a P/E of -4.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.